| Serial Number | 97023072 |
| Word Mark | PHENOMICS HEALTH |
| Filing Date | Sunday, September 12, 2021 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Wednesday, August 14, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Pseudo Mark | PHONEMICS HEALTH |
| Goods and Services | Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions, namely, testing, analysis and evaluation of blood and other biological samples for clinical treatment decision support purposes; Medical testing, analysis, and evaluation services in the nature of testing, analysis and evaluation of blood samples for diagnostic and treatment purposes; Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions in the nature of testing, analysis and evaluation of blood samples for the purpose of combining increased predictability of patient-specific drug efficacy, appropriate dose, drug-drug interactions, and likely adverse drug reactions with precise measurement of patient response to improve patient treatment outcomes, avoid adverse drug reactions, and reduce patient treatment costs |
| Goods and Services | Scientific and technological services featuring testing, analysis and evaluation of human blood and other biological samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services featuring testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; Software as a service (SaaS) services featuring software for use in medical research data collection and management and database management, allowing physicians to share and receive clinical data, monitor patient data, monitor patient clinical data, monitor medications in a patient's circulation to support treatment decisions, develop clinical treatment decision support, develop other medical diagnostic products and prescription drugs for the purpose of improving patient outcomes in the field of healthcare, analyze and record testing, analysis and evaluation of human blood and other biological samples for the purposes of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving the initial drug prescribing practices, and identifying drug-drug interactions; Platform as a Service (PaaS) featuring computer software that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; Providing an interactive website featuring technology that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; scientific and technological services, namely, providing medical and scientific research featuring testing, analysis and evaluation of blood samples for the purpose of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving initial drug prescribing practices, identifying drug-drug interactions, developing clinical treatment decision support, and developing other medical diagnostic products and prescription drugs; scientific and technological services in the nature of testing, analysis and evaluation of blood and other biological samples for research purposes in the field of clinical trials; scientific and technological services, namely, research, analysis, and clinical testing in the fields of precision medicine for the purpose of combining pharmacogenomic drug treatment recommendations, identification and quantitative measurement of patient drug exposure with digital patient monitoring and digital therapy |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, February 1, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 19, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Phenomics Health Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Plymouth, MI 48170 |
| Event Date | Event Description |
| Tuesday, July 5, 2022 | NON-FINAL ACTION E-MAILED |
| Wednesday, September 15, 2021 | NEW APPLICATION ENTERED |
| Tuesday, October 19, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, June 15, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, July 5, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, July 5, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, January 3, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, January 3, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 3, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 1, 2023 | SUSPENSION LETTER WRITTEN |
| Wednesday, February 1, 2023 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, February 1, 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Friday, August 18, 2023 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Wednesday, August 14, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, December 29, 2023 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Wednesday, August 14, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, August 14, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, November 11, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, November 11, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |